Acro Biomedical Co., Ltd. Logo

Acro Biomedical Co., Ltd.

ACBM

(0.8)
Stock Price

0,00 USD

-2308.62% ROA

-2808.91% ROE

-0x PER

Market Cap.

60.042,00 USD

5.29% DER

0% Yield

-2410.24% NPM

Acro Biomedical Co., Ltd. Stock Analysis

Acro Biomedical Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Acro Biomedical Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (4%), which means it has a small amount of debt compared to the ownership it holds

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-3503.95%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-2809.36%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (18.56x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Acro Biomedical Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Acro Biomedical Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Acro Biomedical Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Acro Biomedical Co., Ltd. Revenue
Year Revenue Growth
2015 0
2016 0 0%
2017 510.000 100%
2018 8.014.500 93.64%
2019 193.536 -4041.09%
2020 687.964 71.87%
2021 1.197.500 42.55%
2022 658.500 -81.85%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Acro Biomedical Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 5.285.175 100%
2022 10.080.000 47.57%
2023 7.513.100 -34.17%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Acro Biomedical Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2015 47.490
2016 43.428 -9.35%
2017 53.248 18.44%
2018 317.850 83.25%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Acro Biomedical Co., Ltd. EBITDA
Year EBITDA Growth
2015 -47.490
2016 -43.428 -9.35%
2017 -2.248 -1831.85%
2018 515.550 100.44%
2019 -422.751 221.95%
2020 -130.463 -224.04%
2021 -7.693.578 98.3%
2022 -15.869.737 51.52%
2023 -12.778.800 -24.19%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Acro Biomedical Co., Ltd. Gross Profit
Year Gross Profit Growth
2015 0
2016 0 0%
2017 51.000 100%
2018 833.400 93.88%
2019 12.096 -6789.88%
2020 159.404 92.41%
2021 259.500 38.57%
2022 140.500 -84.7%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Acro Biomedical Co., Ltd. Net Profit
Year Net Profit Growth
2015 -47.490
2016 -43.428 -9.35%
2017 -2.248 -1831.85%
2018 419.660 100.54%
2019 -371.604 212.93%
2020 -117.453 -216.39%
2021 -7.702.078 98.48%
2022 -15.871.443 51.47%
2023 -12.781.956 -24.17%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Acro Biomedical Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2015 0
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Acro Biomedical Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2014 0
2015 -48.850 100%
2016 -34.742 -40.61%
2017 -463.344 92.5%
2018 -140.419 -229.97%
2019 -59.709 -135.17%
2020 -199.460 70.06%
2021 299.335 166.63%
2022 -147.481 302.97%
2023 2.250 6654.71%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Acro Biomedical Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2014 0
2015 -48.850 100%
2016 -34.742 -40.61%
2017 -463.344 92.5%
2018 -140.419 -229.97%
2019 -59.709 -135.17%
2020 -199.460 70.06%
2021 299.335 166.63%
2022 -147.481 302.97%
2023 2.250 6654.71%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Acro Biomedical Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2014 0
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Acro Biomedical Co., Ltd. Equity
Year Equity Growth
2014 10.000
2015 28.635 65.08%
2016 -14.793 293.57%
2017 511.331 102.89%
2018 1.242.154 58.84%
2019 798.239 -55.61%
2020 685.868 -16.38%
2021 643.707 -6.55%
2022 486.370 -32.35%
2023 339.654 -43.2%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Acro Biomedical Co., Ltd. Assets
Year Assets Growth
2014 0
2015 29.460 100%
2016 2.533 -1063.05%
2017 548.310 99.54%
2018 1.482.829 63.02%
2019 932.126 -59.08%
2020 998.053 6.61%
2021 761.077 -31.14%
2022 687.486 -10.7%
2023 539.148 -27.51%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Acro Biomedical Co., Ltd. Liabilities
Year Liabilities Growth
2014 0
2015 825 100%
2016 17.326 95.24%
2017 36.979 53.15%
2018 240.675 84.64%
2019 133.887 -79.76%
2020 312.185 57.11%
2021 117.370 -165.98%
2022 201.116 41.64%
2023 199.494 -0.81%

Acro Biomedical Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.26
Price to Earning Ratio
-0x
Price To Sales Ratio
0.09x
POCF Ratio
-0.41
PFCF Ratio
-0.41
Price to Book Ratio
0.12
EV to Sales
0.12
EV Over EBITDA
-0.01
EV to Operating CashFlow
-0.54
EV to FreeCashFlow
-0.54
Earnings Yield
-264.34
FreeCashFlow Yield
-2.46
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0.22
Graham NetNet
0

Income Statement Metrics

Net Income per Share
-0.26
Income Quality
0.01
ROE
-28.09
Return On Assets
-23.09
Return On Capital Employed
-32.63
Net Income per EBT
1
EBT Per Ebit
1
Ebit per Revenue
-24.1
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
15.31
Stock Based Compensation to Revenue
23.86
Gross Profit Margin
0.21
Operating Profit Margin
-24.1
Pretax Profit Margin
-24.1
Net Profit Margin
-24.1

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0
Return on Tangible Assets
-23.09
Days Sales Outstanding
353.91
Days Payables Outstanding
53.95
Days of Inventory on Hand
8.46
Receivables Turnover
1.03
Payables Turnover
6.76
Inventory Turnover
43.17
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,01
Tangible Book Value per Share
0.01
Shareholders Equity per Share
0.01
Interest Debt per Share
0
Debt to Equity
0.05
Debt to Assets
0.04
Net Debt to EBITDA
-0
Current Ratio
3.27
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
482140
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
12000
Debt to Market Cap
0.43

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Acro Biomedical Co., Ltd. Dividends
Year Dividends Growth

Acro Biomedical Co., Ltd. Profile

About Acro Biomedical Co., Ltd.

Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd. in January 2017. Acro Biomedical Co., Ltd. was incorporated in 2014 and is based in Fishers, Indiana.

CEO
Mr. Pao-Chi Chu
Employee
0
Address
12175 Visionary Way
Fishers, 46038

Acro Biomedical Co., Ltd. Executives & BODs

Acro Biomedical Co., Ltd. Executives & BODs
# Name Age
1 Mr. Pao-Chi Chu
Chief Executive Officer, Chief Financial Officer, President, Secretary & Director
70
2 Mr. Jer-Li Lin
Vice President of Technical
70
3 Mr. Cheng-Hsiang Kao
Managing Director
70
4 Mr. An-Tao Fong
Managing Director
70
5 Mr. Yun-Yuan Chu
Managing Director
70

Acro Biomedical Co., Ltd. Competitors